Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma

Next Previous
Trial Profile

Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide-toniribate (Primary)
  • Indications Biliary cancer; Carcinoma; Non-small cell lung cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PIITCAP
  • Sponsors CellAct Pharma

    • Most Recent Events

    • 22 Feb 2019 Results presented in an Imbrium Therapeutics media release.
    • 22 Feb 2019 According to an Imbrium Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to etoposide toniribate, for the treatment of relapsed refractory biliary tract cancer. Encouraging data in Phase 2 trials were key in securing the ODD.
    • 19 Jan 2019 Results from biliary tract cancer patients (n=22) presented at the 2019 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top